The Latest Cardiac and Vascular News
PLANO, Texas, Sept. 30, 2024 /PRNewswire/ — Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the Intara™ Introducer Sheath and the TLAB®…
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Cortechs.ai, a leader in advanced imaging software medical analysis, is proud to announce a strategic partnership with Ascend Imaging, a premier provider of radiology products and services. This collaboration will enhance Cortechs.ai’s ability to…
– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions by Anjali T. Owens, M.D., Medical Director of the Center for Inherited Cardiac Disease and Assistant Professor of Medicine at the University of Pennsylvania.
DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Monday, September 30, 2024 at 8:00 AM ET. To register, click here.
SAN FRANCISCO, Sept. 26, 2024 /PRNewswire/ — The Journal of Cardiac Failure has published data from the SCALE-HF 1 study on Bodyport Inc.’s, non-invasive biomarker guided technology, showing it predicts heart failure events at twice the rate of weight-based monitoring, with an average…
SEOUL, South Korea, Sept. 25, 2024 /PRNewswire/ — Mediwhale, the AI-powered health diagnostics company, announced $12 million series A2 investments. This funding leverages the momentum of their technological advancements and rapid adoption of its innovative biomarker for preventing…
Gene therapy delivered via CereVasc’s endovascular delivery approach reached key targets in the central nervous system after injection into the cerebellopontine angle resulting in broad biodistribution The eShunt approach has the potential to provide doctors and biopharma partners with a…
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
